Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen- specific IL-4-secreting T cells in multiple sclerosis patients

Clinical Immunology and Immunopathology

Volumn 88, Issue 1, 1998, Pages 28-34

  Takashima, Hiroshi ^a   Smith, Derek R ^a   Fukaura, Hikoaki ^a   Khoury, Samia J ^a   Hafler, David A ^a   Weiner, Howard L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antigen specific T cells; Cyclophosphamide; Eosinophilia; IL 4; Multiple sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 4; METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; EOSINOPHILIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0031828331     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1998.4558     Document Type: Article

References (29)

1. Hafler D. A., Weiner H. L. Immunologic mechanisms and therapy in multiple sclerosis. Immunol. Rev. 144:1995;75-107.
2. Beck J., Rondot P., Catinot L., Falcoff E., Kirchner H., Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbation. Acta Neurol. Scand. 78:1988;318-323.
3. Panitch H. S., Hirsch R. L., Haley A. S., Johnson K. P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1:1987;893-895.
4. Zamvil S., Nelson P., Trotter J. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature. 317:1985;355-358.
5. Tuohy V. K., Sobel R. A., Lees M. B. Myelin proteolipid protein-induced experimental allergic encephalomyelitis. J. Immunol. 140:1988;1868-1873.
6. Linington C., Berger T., Perry L. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur. J. Immunol. 23:1993;1364-1372.
7. Racke M. K., Bonomo A., Scott D. E. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1994;1961-1966.
8. Kuchroo V. K., Das M. P., Brown J. A. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell. 80:1995;707-718.
9. Weiner H. L., Mackin G. A., Orav E. J. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis. Neurology. 43:1993;910-918.
10. Hohol M. J., Olek M. J., Orav J., Stazzone L., Hafler D. A., Khoury S. J., Dawson D. M., Weiner H. L. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprechorisolone: Response to therapy is linked to duration of progressive disease. Neurology. 50:1998;A146.
11. Smith D. R., Balashov K. E., Hafler D. A., Khoury S. J., Weiner H. L. Immune deviation following pulse cyclophosphamide treatment of multiple sclerosis: Increased IL-4 production and associated eosinophilia. Ann. Neurol. 42:1997;313-318.
12. Satoh T., Chen O. J., Sasaki G., Yokozeki H., Katayama I., Nishioki K. Cyclophopsphamide-induced blood and tissue eosinophilia in contact sensitivity: Mechanism of hapten-induced eosinophil recruitment into the skin. Eur. J. Immunol. 27:1997;85-91.
13. Chou F. C. H., Chou C. H. J., Shapira R., Kibler R. F. Basis of microheterogeneity of myelin basic protein. J. Biol. Chem. 251:1976;2671-2679.
14. Bizzozero O. A., Zuniga G., Lees M. B. Fatty acid composition of human myelin proteolipid protein in peroxisomal disorders. J. Neurochem. 56:1991;872-878.
15. Fukaura H., Kent S. C., Pietrusewicz M. J., Khoury S. J., Weiner H. L., Hafler D. A. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-b1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest. 98:1996;70-77.
16. Vadas M. A. Cyclophosphamide pretreatment induces eosinophilia to nonparasite antigens. J. Immunol. 127:1981;2083-2086.
17. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H. L., Hafler D. A. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebral fluid of patients with multiple sclerosis. J. Exp. Med. 179:1994;973-984.
18. Hafler D. A., Orav J., Gertz R., Stazzone L., Weiner H. L. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J. Neuroimmunol. 32:1991;149-158.
19. Lodge P. A., Allegretta M., Steinman L., Sriram S. Myelin basic protein peptide specificity and T-cell receptor gene usage of HPRT mutant T-cell clone in patients with multiple sclerosis. Ann. Neurol. 36:1994;734-740.
20. Sriram S. Longitudinal study of frequency of HPRT mutant T cells in patients with multiple sclerosis. Neurology. 44:1994;311-315.
21. posposin vitro. J. Exp. Med. 179:1994;1285-1295.
22. Sumida T., Sakamoto A., Murata H. Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis. J. Exp. Med. 182:1995;1163-1168.
23. Paul W. E., Seder R. A. Lymphocyte responses and cytokines. Cell. 76:1994;241-251.
24. Fitch F. W., McKisic M. D., Lancki D. W., Gajewski T. F. Differential regulation of murine T lymphocyte subsets. Annu. Rev. Immunol. 11:1993;29-48.
25. Rocken M., Racke M., Shevach E. M. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today. 17:1996;225-231.
26. Comabella, M. Balashor, K. Issazadeh, S. Smith, D. R. Weiner, H. L. Khoury, S. J. Increased IL-12 production by monocytes in patients with progressive multiple sclerosis: Treatment with pulse cyclophosphamide normalizes IL-12 production and induces a Th2 Cytokine Switch, J. Clin. Invest.
27. Gourley M., Austin H. R., Scott D. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann. Int. Med. 125:1996;549-557.
28. Neurology. 43:1993;655-661.
29. Goodkin D. E., Rudick R. A., Mendendorp S. V. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Neurology. 37:1995;30-40.